Antiplatelet therapy: The P2Y12 receptor: No active metabolite, no party

Nature Reviews Cardiology

Volumn 6, Issue 4, 2009, Pages 271-272

  Patrono, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DRUG METABOLITE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PURINERGIC P2 RECEPTOR; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; CORONARY ARTERY DISEASE; DRUG METABOLISM; DRUG RESPONSE; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; THROMBOCYTE AGGREGATION INHIBITION; BIOAVAILABILITY; BIOTRANSFORMATION; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG ANTAGONISM; DRUG INTERACTION; DRUG RESISTANCE; GENETICS; METABOLISM; NOTE; TREATMENT FAILURE;

ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DRUG INTERACTIONS; DRUG RESISTANCE; GENETIC VARIATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; TICLOPIDINE; TREATMENT FAILURE;

EID: 67649635751     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.29     Document Type: Short Survey

References (9)

1. De Miguel, A., ibanez, B. & Badimón, J. J. Clinical implications of clopidogrel resistance. Thromb. Haemost. 100, 196-203 (2008).
2. wallentin, L. et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirintreated patients with coronary artery disease. Eur. Heart J. 29, 21-30 (2008).
3. erlinge, D. et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll. Cardiol. 52, 1968-1977 (2008).
4. Patrono, C., Baigent, C., Hirsh, J. & Roth, G. Antiplatelet drugs: American College of Chest Physicians evidence-Based Clinical Practice Guidelines (8th edition). Chest 133, 199s-233s (2008). (Pubitemid 351894914)
5. wiviott, s. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
6. Järemo, P., Lindahl, T. L., Fransson, s. G. & Richter, A. individual variations of platelet inhibition after loading doses of clopidogrel. J. Intern. Med. 252, 233-238 (2002).
7. Mega, J. L. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
8. santilli, F. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J. Am. Coll. Cardiol. 53, 667-677 (2009).
9. Freedman, J. E. & Hylek, e. M. Clopidogrel, genetics, and drug responsiveness. N. Engl. J. Med. 360, 411-413 (2009).